The oral immuno-oncology drug is designed to hinder key pathways that may enhance the effectiveness of cancer treatments. Credit: Viacheslav Lopatin / Shutterstock.

South Korean biopharmaceutical company TiumBio has submitted an investigational new drug application to the Korean Ministry of Food and Drug Safety for a Phase IIa clinical trial of TU2218, an oral immuno-oncology drug intended to treat cancer.

TU2218 is a dual inhibitor that targets the transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2), with the aim of hindering pathways that are known to impact the activity of immuno-oncology drugs.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The drug is currently being studied in a Phase Ib clinical trial in the US along with Keytruda (pembrolizumab) for treating advanced solid tumours.

The upcoming Phase IIa study will focus on biliary tract cancer (BTC), head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC), which have historically shown low response rates to existing therapies.

The Phase IIa trial aims to enrol up to 116 subjects across three cohorts, with up to 40 participants for BTC, up to 36 for HNSCC and up to 40 for CRC.

See Also:

It will assess the efficacy and safety of TU2218 administered alongside pembrolizumab.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TiumBio expects that the combination regimen will lead to improved response rates in these types of tumours.

In preparation for the trial, the company has conducted in vivo efficacy studies using syngeneic tumour models, including 4T1, MC39 and CT26.

TiumBio founder and CEO Hun-taek Kim said: “We believe that the results of this TU2218 triple combination regimen show substantial potential in enhancing anticancer efficacy.

“The three indications we selected are diseases characterised by high expression of the target protein TGF-beta within the microenvironment, coupled with a significant unmet medical need attributed to low response rates to anti-PD-1 therapies.

“We will develop TU2218 as a safer and more effective novel drug to increase clinical benefits of the immune checkpoint inhibitors in this area.”